Zobrazeno 1 - 10
of 180
pro vyhledávání: '"EF24"'
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Cancer Cell International, Vol 21, Iss 1, Pp 1-13 (2021)
Abstract Background The role of Diphenyldifluoroketone (EF24), a synthetic analogue of curcumin with noteworthy antitumor potential, remains unclear in non-small cell lung cancer (NSCLC). Herein, the inhibitory effect of EF24 on NSCLC and its mechani
Externí odkaz:
https://doaj.org/article/fb291020b8ab40cd8b1c2b4dea69cd57
Publikováno v:
Pharmaceutics, Vol 15, Iss 7, p 1921 (2023)
Pancreatic carcinoma is a cancer disease with high mortality. Thus, new and efficient treatments for this disease are badly needed. Curcumin has previously shown promising effects in pancreatic cancer patients; however, this natural compound suffers
Externí odkaz:
https://doaj.org/article/6496dab7061a48e29fee709ff8caf30f
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Molecules, Vol 26, Iss 20, p 6302 (2021)
The natural compound curcumin has been shown to have therapeutic potential against a wide range of diseases such as cancer. Curcumin reduces cell viability of renal cell carcinoma (RCC) cells when combined with TNF-related apoptosis-inducing ligand (
Externí odkaz:
https://doaj.org/article/85d500f288014bebaf259e8403ff8db3
Publikováno v:
Pharmaceutics; Volume 15; Issue 7; Pages: 1921
Pancreatic carcinoma is a cancer disease with high mortality. Thus, new and efficient treatments for this disease are badly needed. Curcumin has previously shown promising effects in pancreatic cancer patients; however, this natural compound suffers
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::79278856b61c810db13552598a49c61e
Autor:
Weiqian Chen, Peng Zou, Zhongwei Zhao, Xi Chen, Xiaoxi Fan, Rajamanickam Vinothkumar, Ri Cui, Fazong Wu, Qianqian Zhang, Guang Liang, Jiansong Ji
Publikováno v:
Redox Biology, Vol 10, Iss C, Pp 78-89 (2016)
Mechanistic/mammalian target of rapamycin (mTOR) has emerged as a new potential therapeutic target for gastric cancer. Rapamycin and rapamycin analogs are undergoing clinical trials and have produced clinical responses in a subgroup of cancer patient
Externí odkaz:
https://doaj.org/article/27047cfbadac48d2bd883cd78974aa73
Publikováno v:
Frontiers in Oncology, Vol 8 (2018)
Curcumin is an attractive agent due to its multiple bioactivities. However, the low oral bioavailability and efficacy profile hinders its clinical application. To improve the bioavailability, many analogs of curcumin have been developed, among which
Externí odkaz:
https://doaj.org/article/2063e82609d24a1aba0b92070365cc1c
Autor:
Geeta Rao, Gregory Nkepang, Jian Xu, Hooman Yari, Hailey Houson, Chengwen Teng, Vibhudutta Awasthi
Publikováno v:
Frontiers in Chemistry, Vol 6 (2018)
The proteasome is a validated target in drug discovery for diseases associated with unusual proteasomal activity. Here we report that two diphenyldihaloketones, CLEFMA and EF24, inhibit the peptidase activity of the 26S proteasome. The objective of t
Externí odkaz:
https://doaj.org/article/218c17449aca491298e4df305958d3bf